Work

AVENANCE real-world study of avelumab first-line (1L) maintenance treatment for advanced urothelial carcinoma (UC): Analyses in low tumor burden subgroups.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.718

Authors: Philippe Barthelemy, Yohann Loriot, Constance Thibault, Aude Flechon, Eric Voog, Jean Christophe Eymard, Camille Simon, Damien Pouessel, Matthieu Chasseray, Veronique Lorgis, Constant Josse, Prisca Lambert, Laurent Paret, Marine Gross-Goupil

Institutions: Institut de Cancérologie Strasbourg, Université Paris-Saclay, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Centre Léon Bérard, Centre Jean Bernard, Institut Jean Godinot, Institut de Cancérologie de Lorraine, Institut universitaire du cancer de Toulouse Oncopole, Institut de Cancérologie de Bourgogne, Pfizer (France), Merck KGaA, Darmstadt (Germany), Centre Hospitalier Universitaire de Bordeaux

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

OpenAlex ID: W4407700586

Cites:

Cited by: 1

Related to: 10